REMS Not Anticipated For Every NME – FDA Official
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's Sandra Kweder aims to allay industry worries at Drug Industry Association meeting in Boston.
You may also be interested in...
Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword
Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.
Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword
Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.
Post-marketing Study Mandates Could Drive R&D Strategy – DIA Panel
Companies should include post-market “burden” in calculus of drug development decisions, Tufts analyst suggests.